BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29899382)

  • 1. Constitutive IP
    Bittremieux M; La Rovere RM; Akl H; Martines C; Welkenhuyzen K; Dubron K; Baes M; Janssens A; Vandenberghe P; Laurenti L; Rietdorf K; Morciano G; Pinton P; Mikoshiba K; Bootman MD; Efremov DG; De Smedt H; Parys JB; Bultynck G
    Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G
    Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    Akl H; La Rovere RM; Janssens A; Vandenberghe P; Parys JB; Bultynck G
    Int J Dev Biol; 2015; 59(7-9):391-8. PubMed ID: 26260683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
    Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca
    Kerkhofs M; La Rovere R; Welkenhuysen K; Janssens A; Vandenberghe P; Madesh M; Parys JB; Bultynck G
    Cell Calcium; 2021 Mar; 94():102333. PubMed ID: 33450506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular and ER-stored Ca
    Bittremieux M; La Rovere RM; Schuermans M; Luyten T; Mikoshiba K; Vangheluwe P; Parys JB; Bultynck G
    Cell Death Discov; 2018; 4():101. PubMed ID: 30416758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bcl-2-IP
    Distelhorst CW
    Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.
    Vervloessem T; Akl H; Tousseyn T; De Smedt H; Parys JB; Bultynck G
    Oncotarget; 2017 Dec; 8(67):111656-111671. PubMed ID: 29340082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
    Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
    Rong YP; Aromolaran AS; Bultynck G; Zhong F; Li X; McColl K; Matsuyama S; Herlitze S; Roderick HL; Bootman MD; Mignery GA; Parys JB; De Smedt H; Distelhorst CW
    Mol Cell; 2008 Jul; 31(2):255-65. PubMed ID: 18657507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 and IP
    Ivanova H; Wagner LE; Tanimura A; Vandermarliere E; Luyten T; Welkenhuyzen K; Alzayady KJ; Wang L; Hamada K; Mikoshiba K; De Smedt H; Martens L; Yule DI; Parys JB; Bultynck G
    Cell Mol Life Sci; 2019 Oct; 76(19):3843-3859. PubMed ID: 30989245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP
    Distelhorst CW; Bootman MD
    Cold Spring Harb Perspect Biol; 2019 Sep; 11(9):. PubMed ID: 31110129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
    Monaco G; Vervliet T; Akl H; Bultynck G
    Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.
    Zhong F; Harr MW; Bultynck G; Monaco G; Parys JB; De Smedt H; Rong YP; Molitoris JK; Lam M; Ryder C; Matsuyama S; Distelhorst CW
    Blood; 2011 Mar; 117(10):2924-34. PubMed ID: 21193695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracing the evolutionary history of Ca
    Rosa N; Shabardina V; Ivanova H; Sebé-Pedrós A; Yule DI; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2021 Nov; 1868(12):119121. PubMed ID: 34400171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
    Rong YP; Barr P; Yee VC; Distelhorst CW
    Biochim Biophys Acta; 2009 Jun; 1793(6):971-8. PubMed ID: 19056433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
    Rong YP; Bultynck G; Aromolaran AS; Zhong F; Parys JB; De Smedt H; Mignery GA; Roderick HL; Bootman MD; Distelhorst CW
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14397-402. PubMed ID: 19706527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.
    Vervliet T; Parys JB; Bultynck G
    Biochem Soc Trans; 2015 Jun; 43(3):396-404. PubMed ID: 26009182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.
    Greenberg EF; McColl KS; Zhong F; Wildey G; Dowlati A; Distelhorst CW
    Cell Death Dis; 2015 Dec; 6(12):e2034. PubMed ID: 26720343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
    Ivanova H; Ritaine A; Wagner L; Luyten T; Shapovalov G; Welkenhuyzen K; Seitaj B; Monaco G; De Smedt H; Prevarskaya N; Yule DI; Parys JB; Bultynck G
    Oncotarget; 2016 Aug; 7(34):55704-55720. PubMed ID: 27494888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.